Getinge


Softer end to 2025, but underlying performance was not bad

05/02/26 -"Our estimates have been moderated following the Q4 25 miss, primarily reflecting a softer order book and growth momentum (especially for the LS segment), and the continued drag on profitability from ..."

Pages
63
Language
English
Published on
05/02/26
You may also be interested by these reports :
16/02/26
The target price benefits from higher earnings expectations, along with a 20% premium added to the peer-based valuation. This reflects the firm’s ...

13/02/26
Dominant positioning for critical medical equipment (such as ventilators and heart-lung machines) in hospitals’ operating rooms, with two-thirds ...

12/02/26
CZM reported weak Q1 results, with challenges in both ophthalmology and microsurgery. Profitability declined significantly due to FX headwinds, an ...

11/02/26
4Q sales increased 12.1% YoY (18.4% at constant currency) to €7.6bn, mainly driven by strong growth in AI glasses. However, this category continues ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO